AXL as a Target in Breast Cancer Therapy

Figure 1

In breast cancer, AXL (orange) can be activated through either binding of GAS6 (purple) or through interaction with other receptors (green) to activate a variety of downstream signaling pathways (gray). Cleavage by ADAM10/17 (red) can result in release of the extracellular domain which retains ligand-binding abilities.